Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arete Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Arete Therapeutics launched in 2003 with a straightforward therapeutic and commercial goal: to develop a new treatment for high blood pressure that works by blocking the s-EH enzyme. Arete began enrolling patients for its first human trial in November 2007, and its oral inhibitor of s-EH proved safe. By the time the safety data were released a year later, Arete's strategy had been further refined and the company was envisioning the compound as a potential therapy for metabolic syndrome. Based on data from preclinical studies, Arete now posits that its therapy can become a treatment for type 2 diabetes.
Advertisement

Related Content

Start-Up Previews (03/2009)
Start-Up Previews (03/2009)

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel